Literature DB >> 31932455

The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Britton Trabert1, Shelley S Tworoger2, Katie M O'Brien3, Mary K Townsend2, Renée T Fortner4, Edwin S Iversen5, Patricia Hartge6, Emily White7, Pilar Amiano8,9, Alan A Arslan10,11, Leslie Bernstein12, Louise A Brinton6, Julie E Buring13,14, Laure Dossus15, Gary E Fraser16, Mia M Gaudet17, Graham G Giles18,19,20, Inger T Gram21, Holly R Harris7,22, Judith Hoffman Bolton23, Annika Idahl24, Michael E Jones25, Rudolf Kaaks4, Victoria A Kirsh26, Synnove F Knutsen16, Marina Kvaskoff27,28, James V Lacey12, I-Min Lee13,14, Roger L Milne18, N Charlotte Onland-Moret29, Kim Overvad30, Alpa V Patel17, Ulrike Peters7, Jenny N Poynter31, Elio Riboli32, Kim Robien33, Thomas E Rohan34, Dale P Sandler3, Catherine Schairer6, Leo J Schouten35, Veronica W Setiawan36, Anthony J Swerdlow37, Ruth C Travis38, Antonia Trichopoulou39, Piet A van den Brandt35, Kala Visvanathan21, Lynne R Wilkens40, Alicja Wolk41,42, Anne Zeleniuch-Jacquotte10,11, Nicolas Wentzensen.   

Abstract

Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (<294) [HR (95% confidence interval): 1.92 (1.60-2.30)]. Risk increased 14% per 5-year increase in LOC (60 cycles) [(1.10-1.17)]; this association remained after adjustment for LOC components: number of pregnancies and oral contraceptive use [1.08 (1.04-1.12)]. The association varied by histotype, with increased risk of serous [1.13 (1.09-1.17)], endometrioid [1.20 (1.10-1.32)], and clear cell [1.37 (1.18-1.58)], but not mucinous [0.99 (0.88-1.10), P-heterogeneity = 0.01] tumors. Heterogeneity across histotypes was reduced [P-heterogeneity = 0.15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous]. Although the 10-year absolute risk of ovarian cancer is small, it roughly doubles as the number of LOC rises from approximately 300 to 500. The consistency and linearity of effects strongly support the hypothesis that each ovulation leads to small increases in the risk of most ovarian cancers, a risk that cumulates through life, suggesting this as an important area for identifying intervention strategies. SIGNIFICANCE: Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31932455      PMCID: PMC7056529          DOI: 10.1158/0008-5472.CAN-19-2850

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.

Authors:  Kathryn L Terry; Linda Titus-Ernstoff; John R McKolanis; William R Welch; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

Review 2.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

3.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

4.  Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Authors:  Jennifer Ose; Elizabeth M Poole; Helena Schock; Matti Lehtinen; Alan A Arslan; Anne Zeleniuch-Jacquotte; Kala Visvanathan; Kathy Helzlsouer; Julie E Buring; I-Min Lee; Anne Tjønneland; Laure Dossus; Antonia Trichopoulou; Giovanna Masala; N Charlotte Onland-Moret; Elisabete Weiderpass; Eric J Duell; Annika Idahl; Ruth C Travis; Sabina Rinaldi; Melissa A Merritt; Britton Trabert; Nicolas Wentzensen; Shelley S Tworoger; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

5.  Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer.

Authors:  P M Webb; A Green; M C Cummings; D M Purdie; M D Walsh; G Chenevix-Trench
Journal:  J Natl Cancer Inst       Date:  1998-11-18       Impact factor: 13.506

6.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.

Authors:  Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

7.  "Incessant ovulation" and ovarian cancer.

Authors:  J T Casagrande; E W Louie; M C Pike; S Roy; R K Ross; B E Henderson
Journal:  Lancet       Date:  1979-07-28       Impact factor: 79.321

8.  Menstrual and reproductive factors in relation to ovarian cancer risk.

Authors:  L Titus-Ernstoff; K Perez; D W Cramer; B L Harlow; J A Baron; E R Greenberg
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

9.  Incessant ovulation and ovarian cancer - a hypothesis re-visited.

Authors:  M F Fathalla
Journal:  Facts Views Vis Obgyn       Date:  2013

10.  Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Kara A Michels; Garnet L Anderson; Louise A Brinton; Roni T Falk; Ashley M Geczik; Holly R Harris; Kathy Pan; Ruth M Pfeiffer; Lihong Qi; Thomas Rohan; Nicolas Wentzensen; Xia Xu
Journal:  Int J Cancer       Date:  2019-02-15       Impact factor: 7.316

View more
  12 in total

1.  Early life physical activity and risk of ovarian cancer in adulthood.

Authors:  Tianyi Wang; Danielle E Jake-Schoffman; Mary K Townsend; Christine Vinci; Walter C Willett; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2021-08-21       Impact factor: 7.396

2.  Application Value of Combined Detection of DCE-MRI and Serum Tumor Markers HE4, Ki67, and HK10 in the Diagnosis of Ovarian Cancer.

Authors:  Quanzhi Wang; Hui Dong; Peng Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-06-14       Impact factor: 3.009

3.  Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).

Authors:  Mary K Townsend; Britton Trabert; Renée T Fortner; Alan A Arslan; Julie E Buring; Brian D Carter; Graham G Giles; Sarah R Irvin; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Woon-Puay Koh; James V Lacey; Hilde Langseth; Susanna C Larsson; I-Min Lee; María Elena Martínez; Melissa A Merritt; Roger L Milne; Katie M O'Brien; Michael J Orlich; Julie R Palmer; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Kim Robien; Thomas E Rohan; Lynn Rosenberg; Sven Sandin; Dale P Sandler; Leo J Schouten; V Wendy Setiawan; Anthony J Swerdlow; Giske Ursin; Piet A van den Brandt; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Shelley S Tworoger; Nicolas Wentzensen
Journal:  Int J Epidemiol       Date:  2022-06-13       Impact factor: 9.685

4.  Lifetime ovulatory years and ovarian cancer gene expression profiles.

Authors:  Naoko Sasamoto; Paul A Stewart; Tianyi Wang; Sean J Yoder; Srikumar Chellappan; Jonathan L Hecht; Brooke L Fridley; Kathryn L Terry; Shelley S Tworoger
Journal:  J Ovarian Res       Date:  2022-05-13       Impact factor: 5.506

5.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

6.  Long non-coding RNA PVT1-mediated miR-543/SERPINI1 axis plays a key role in the regulatory mechanism of ovarian cancer.

Authors:  Chong Qu; Chunmei Dai; Yahua Guo; Rui Qin; Junbao Liu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

Review 7.  Progesterone Receptor Membrane Component (PGRMC)1 and PGRMC2 and Their Roles in Ovarian and Endometrial Cancer.

Authors:  John J Peluso; James K Pru
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

8.  Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation.

Authors:  Hsuan-Shun Huang; Pao-Chu Chen; Sung-Chao Chu; Ming-Hsun Lee; Chi-Ya Huang; Tang-Yuan Chu
Journal:  Neoplasia       Date:  2021-10-21       Impact factor: 5.715

Review 9.  Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.

Authors:  David Samuel; Alexandra Diaz-Barbe; Andre Pinto; Matthew Schlumbrecht; Sophia George
Journal:  Cells       Date:  2022-02-04       Impact factor: 6.600

10.  Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Authors:  Naoko Sasamoto; Ana Babic; Allison F Vitonis; Linda Titus; Daniel W Cramer; Britton Trabert; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.